poliomyelitis
Information
- Disease name
- poliomyelitis
- Disease ID
- DOID:4953
- Description
- "A viral infectious disease that results in destruction located in motor neurons, has_material_basis_in Human poliovirus 1, has_material_basis_in Human poliovirus 2, or has_material_basis_in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis." [url:http\://en.wikipedia.org/wiki/Poliomyelitis, url:http\://www.cdc.gov/vaccines/pubs/pinkbook/downloads/polio.pdf, url:http\://www.mayoclinic.com/health/polio/DS00572/DSECTION=symptoms]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06101173 | Active, not recruiting | Phase 1 | A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults | January 15, 2024 | September 3, 2024 |
| NCT02089880 | Active, not recruiting | N/A | Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis | February 2014 | December 2023 |
| NCT05327426 | Active, not recruiting | Phase 1 | Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT | April 1, 2022 | August 25, 2024 |
| NCT05677256 | Active, not recruiting | Phase 4 | A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 | November 9, 2023 | July 25, 2024 |
| NCT00138268 | Completed | Pilot Study Freeze and Transport Immune Cells | February 2005 | ||
| NCT00146835 | Completed | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine | April 2003 | June 2006 | |
| NCT00254969 | Completed | Phase 3 | Immunogenicity and Safety of Pentaxim in South African Infants | October 2005 | January 2010 |
| NCT00255021 | Completed | Phase 4 | Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand | December 2005 | January 2009 |
| NCT00258843 | Completed | Phase 3 | Safety of Imovax Polio in Chinese Infants and Children | November 2005 | April 2006 |
| NCT00287092 | Completed | Phase 3 | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants | February 2006 | September 2008 |
| NCT00303316 | Completed | Phase 3 | Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants | February 2006 | September 2007 |
| NCT00304265 | Completed | Phase 4 | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine | March 2006 | October 2007 |
| NCT00307567 | Completed | Phase 2 | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 | November 2005 | March 2006 |
| NCT00316147 | Completed | Phase 3 | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules | December 2005 | August 2006 |
| NCT00319852 | Completed | Phase 3 | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV | April 2006 | July 2008 |
| NCT00320463 | Completed | Phase 3 | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants | April 2006 | January 2007 |
| NCT00325143 | Completed | Phase 3 | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine | December 1, 2003 | February 1, 2007 |
| NCT00325156 | Completed | Phase 4 | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants | November 2, 2004 | August 23, 2007 |
| NCT00337428 | Completed | Phase 3 | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) | May 2006 | May 2007 |
| NCT00343421 | Completed | Phase 3 | Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers | July 2006 | June 2009 |
| NCT00348387 | Completed | Phase 3 | Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV | June 2006 | December 2008 |
| NCT00352963 | Completed | Phase 3 | Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). | September 30, 2003 | July 16, 2004 |
| NCT00355121 | Completed | Phase 2 | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® | October 2006 | July 2009 |
| NCT00376779 | Completed | Phase 2 | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age | October 2006 | May 2007 |
| NCT00404651 | Completed | Phase 3 | Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants | November 2006 | July 2008 |
| NCT00432042 | Completed | Phase 3 | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) | January 12, 2007 | March 27, 2008 |
| NCT00447525 | Completed | Phase 3 | REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children | February 2007 | January 2008 |
| NCT00453570 | Completed | Phase 3 | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months | March 2007 | January 2009 |
| NCT00463437 | Completed | Phase 3 | Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines | April 25, 2007 | June 14, 2008 |
| NCT00514033 | Completed | A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children | July 2007 | July 2011 | |
| NCT00604058 | Completed | Phase 2 | Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly | January 2008 | December 2008 |
| NCT00611559 | Completed | Phase 4 | Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children | February 14, 2008 | June 25, 2008 |
| NCT00627458 | Completed | Phase 2 | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine | February 1, 2008 | August 18, 2008 |
| NCT00635128 | Completed | Phase 4 | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine | February 1, 2008 | July 8, 2008 |
| NCT00654901 | Completed | Phase 3 | Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ | March 2008 | July 2009 |
| NCT00753649 | Completed | Phase 4 | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants | September 23, 2008 | March 12, 2013 |
| NCT00797511 | Completed | Phase 3 | Immunogenicity and Safety of Adacel Polio Vaccine | November 2008 | July 2009 |
| NCT00831311 | Completed | Phase 2 | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants | October 2004 | March 2007 |
| NCT00871000 | Completed | Phase 3 | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. | April 1, 2009 | November 18, 2009 |
| NCT00879827 | Completed | Phase 3 | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants | September 2000 | May 2001 |
| NCT00885157 | Completed | Phase 2 | Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly | April 2009 | December 2009 |
| NCT00920439 | Completed | Phase 3 | Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers | June 1, 2009 | August 3, 2009 |
| NCT00937404 | Completed | Phase 1 | Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants | August 4, 2009 | November 13, 2009 |
| NCT00964028 | Completed | Phase 3 | Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) | December 1, 2009 | April 12, 2010 |
| NCT00970307 | Completed | Phase 2 | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age | August 13, 2009 | January 27, 2010 |
| NCT01021293 | Completed | Phase 3 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine | November 28, 2009 | July 5, 2010 |
| NCT01031303 | Completed | Phase 4 | Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age | December 2009 | January 2011 |
| NCT01048190 | Completed | Phase 1 | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains | August 2008 | March 2009 |
| NCT01056705 | Completed | Phase 2 | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV) | July 2009 | August 2010 |
| NCT01086423 | Completed | Phase 3 | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine | March 1, 2010 | November 19, 2010 |
| NCT01090453 | Completed | Phase 2 | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants | May 17, 2010 | October 11, 2011 |
| NCT01094171 | Completed | Phase 4 | Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia | December 3, 2010 | October 27, 2012 |
| NCT01105559 | Completed | Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine | April 2010 | December 2011 | |
| NCT01171989 | Completed | Phase 2 | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose | August 18, 2010 | December 3, 2010 |
| NCT01177722 | Completed | Phase 3 | A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants | August 2010 | December 2011 |
| NCT01214889 | Completed | Phase 3 | Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. | September 2010 | December 2011 |
| NCT01229579 | Completed | N/A | Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan | May 2010 | January 2011 |
| NCT01244464 | Completed | Phase 4 | A Study of the Safety of IMOVAX Polio™ in China | November 2010 | December 2011 |
| NCT01245049 | Completed | Phase 3 | Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children | April 1, 2011 | April 2, 2012 |
| NCT01248884 | Completed | Phase 2 | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) | December 9, 2010 | January 5, 2012 |
| NCT01249183 | Completed | Phase 3 | Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old | October 2010 | September 2011 |
| NCT01278433 | Completed | Phase 4 | A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China | December 2010 | June 2012 |
| NCT01287949 | Completed | Phase 3 | Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older | January 2011 | May 2012 |
| NCT01309646 | Completed | Phase 3 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine | March 4, 2011 | February 24, 2012 |
| NCT01323647 | Completed | Phase 3 | Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers | April 25, 2011 | September 19, 2011 |
| NCT01323959 | Completed | Phase 4 | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults | April 1, 2011 | March 1, 2012 |
| NCT01353703 | Completed | Phase 3 | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine | April 16, 2012 | February 25, 2013 |
| NCT01358825 | Completed | Phase 4 | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ | May 30, 2011 | July 15, 2011 |
| NCT01389687 | Completed | Phase 3 | Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan | July 2011 | January 2012 |
| NCT01437423 | Completed | Phase 4 | Regulatory Post-Marketing Surveillance Study for TETRAXIM™ | June 2011 | November 2015 |
| NCT01444781 | Completed | Phase 3 | Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants | September 2011 | October 2013 |
| NCT01453998 | Completed | Phase 2 | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) | October 14, 2011 | November 12, 2012 |
| NCT01457495 | Completed | Phase 2 | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly | September 1998 | September 1999 |
| NCT01457508 | Completed | Phase 3 | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately | January 1999 | March 2000 |
| NCT01457547 | Completed | Phase 4 | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course | October 2003 | May 2005 |
| NCT01457560 | Completed | Phase 3 | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine | February 2000 | April 2001 |
| NCT01475539 | Completed | Phase 4 | Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine | November 2011 | November 2013 |
| NCT01510366 | Completed | Phase 3 | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) | January 2012 | September 2015 |
| NCT01546909 | Completed | Phase 4 | Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE | February 2012 | December 2012 |
| NCT01568060 | Completed | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea | May 21, 2012 | December 15, 2015 | |
| NCT01571505 | Completed | Phase 1 | Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) | March 1, 2012 | November 30, 2016 |
| NCT01573936 | Completed | N/A | Quality of Life in Adult Neurological Patients | January 2008 | December 2011 |
| NCT01577732 | Completed | Phase 3 | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers | December 8, 2012 | April 9, 2013 |
| NCT01708720 | Completed | Phase 1 | Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults | August 2011 | February 2012 |
| NCT01709071 | Completed | Phase 1/Phase 2 | Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants | February 2012 | May 2013 |
| NCT01813604 | Completed | Phase 3 | Immunogenicity of Inactivated and Live Polio Vaccines | November 2012 | November 2013 |
| NCT01831050 | Completed | Phase 4 | Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine | May 2013 | December 2014 |
| NCT01847872 | Completed | Phase 4 | IPV Clinical Trial - The Gambia | July 2013 | July 2015 |
| NCT01948193 | Completed | Phase 3 | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth | February 2014 | June 2015 |
| NCT01983540 | Completed | Phase 3 | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination | October 2013 | December 2015 |
| NCT01997632 | Completed | Phase 1 | Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults | November 2013 | May 2014 |
| NCT02005536 | Completed | Phase 4 | Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan | December 2013 | October 2014 |
| NCT02040636 | Completed | Phase 2 | Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis | January 1999 | May 2000 |
| NCT02094833 | Completed | Phase 3 | DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants | March 2014 | November 2016 |
| NCT02096263 | Completed | Phase 3 | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants | April 16, 2014 | November 13, 2015 |
| NCT02189811 | Completed | Phase 4 | Polio End-game Strategies - Poliovirus Type 2 Challenge Study | September 2014 | May 2016 |
| NCT02231632 | Completed | Phase 2/Phase 3 | The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) | January 2011 | August 2012 |
| NCT02274285 | Completed | Phase 3 | DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants | October 2014 | May 28, 2016 |
| NCT02291263 | Completed | Phase 3 | Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine | October 2014 | August 2015 |
| NCT02347423 | Completed | Phase 2 | 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants | February 2015 | September 26, 2015 |
| NCT02412514 | Completed | Phase 4 | Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules | April 2015 | December 2015 |
| NCT02422264 | Completed | Phase 4 | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery | January 22, 2016 | March 7, 2018 |
| NCT02428491 | Completed | Phase 3 | Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth | April 20, 2015 | January 11, 2017 |
| NCT02434770 | Completed | Phase 3 | Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine | August 2015 | June 17, 2016 |
| NCT02458183 | Completed | Phase 3 | Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS | February 2, 2015 | May 5, 2018 |
| NCT02580201 | Completed | Phase 4 | A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age | November 2015 | August 11, 2016 |
| NCT02582255 | Completed | Phase 4 | A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania | November 2015 | December 22, 2016 |
| NCT02643368 | Completed | Phase 4 | Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine | December 2015 | February 2016 |
| NCT02643446 | Completed | Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine | August 2015 | July 2017 | |
| NCT02775942 | Completed | Phase 2 | Safety and Immunogenicity of IPOVAC in Young Children | November 2015 | October 31, 2016 |
| NCT02785705 | Completed | Phase 3 | Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine | April 2015 | August 2015 |
| NCT02847026 | Completed | Phase 4 | Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study | September 2016 | May 2017 |
| NCT02853929 | Completed | Phase 4 | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery | September 19, 2016 | March 19, 2019 |
| NCT02967783 | Completed | N/A | A Campaign-based ID fIPV Administration Trial | February 7, 2017 | September 18, 2018 |
| NCT02985320 | Completed | Phase 1/Phase 2 | Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine | October 2016 | June 2017 |
| NCT03614702 | Completed | Phase 3 | Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV | September 15, 2015 | August 2016 |
| NCT00092469 | Completed | Phase 3 | Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) | March 2002 | August 2003 |
| NCT00133445 | Completed | Phase 2 | Pentavalent DTaP-Hep B-IPV | December 2005 | August 2006 |
| NCT00137696 | Completed | N/A | Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine | July 2003 | July 2004 |
| NCT03597919 | Completed | Phase 4 | A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. | May 28, 2018 | January 15, 2020 |
| NCT00001185 | Completed | Study of "Post-Polio Syndrome" | June 1982 | May 2003 | |
| NCT03671616 | Completed | Phase 3 | Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months | May 15, 2018 | October 3, 2018 |
| NCT03722004 | Completed | Phase 4 | Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study | December 18, 2018 | December 19, 2019 |
| NCT03723837 | Completed | Phase 4 | Persistence of IPV Immunity | November 21, 2018 | July 30, 2019 |
| NCT03822754 | Completed | Phase 3 | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants | June 6, 2018 | December 11, 2018 |
| NCT03822767 | Completed | Phase 3 | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants | June 12, 2018 | December 11, 2018 |
| NCT03891758 | Completed | Phase 3 | Confirmatory Study of BK1310 in Healthy Infants | April 1, 2019 | August 10, 2020 |
| NCT04080687 | Completed | Effect of Ankle-foot Orthoses on Balance Confidence | February 6, 2020 | February 12, 2021 | |
| NCT04220515 | Completed | Phase 4 | Inactivated Poliomyelitis Vaccine Made From Sabin Strain | February 8, 2018 | October 14, 2019 |
| NCT04224519 | Completed | Phase 4 | Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain | April 15, 2018 | October 12, 2019 |
| NCT04386707 | Completed | Phase 3 | Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine | May 11, 2020 | October 20, 2020 |
| NCT04432935 | Completed | N/A | Effect of Lactoferrin on Polio Seroconversion | October 1, 2020 | June 30, 2022 |
| NCT04448132 | Completed | Phase 4 | Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) | November 20, 2020 | May 3, 2021 |
| NCT04529538 | Completed | Phase 1 | Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines | March 26, 2021 | February 17, 2023 |
| NCT04544787 | Completed | Phase 2 | A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates | October 22, 2018 | May 8, 2019 |
| NCT04579510 | Completed | Phase 2 | Immunogenicity nOPV2 With and Without bOPV | February 8, 2021 | December 23, 2021 |
| NCT04614597 | Completed | A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China | October 29, 2020 | December 21, 2021 | |
| NCT04618783 | Completed | N/A | Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization | July 20, 2019 | January 10, 2020 |
| NCT04693286 | Completed | Phase 2 | Clinical Trial of Novel OPV2 Vaccine | September 21, 2020 | August 30, 2021 |
| NCT04989231 | Completed | An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses | September 9, 2021 | December 25, 2022 | |
| NCT05033561 | Completed | Phase 3 | Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants | December 16, 2021 | October 25, 2022 |
| NCT05163561 | Completed | Phase 3 | Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine | January 9, 2022 | April 29, 2023 |
| NCT05386810 | Completed | Phase 3 | Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants | November 5, 2020 | July 20, 2023 |
| NCT05432141 | Completed | Phase 4 | A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants | June 13, 2022 | December 13, 2022 |
| NCT03025750 | Completed | Phase 3 | Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age | January 19, 2017 | November 14, 2017 |
| NCT03032419 | Completed | Phase 3 | Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months | February 6, 2017 | March 12, 2018 |
| NCT03169725 | Completed | Phase 2/Phase 3 | A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants | May 31, 2017 | June 14, 2019 |
| NCT03202719 | Completed | Phase 4 | Duration of IPV Priming and Antibody Decay | November 5, 2017 | October 1, 2019 |
| NCT03208101 | Completed | Phase 1 | A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults | July 3, 2017 | December 21, 2017 |
| NCT03239496 | Completed | Phase 3 | A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV | October 23, 2017 | November 13, 2018 |
| NCT03430349 | Completed | Phase 1 | Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults | May 16, 2017 | October 27, 2017 |
| NCT03526978 | Completed | Phase 3 | An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants | August 8, 2017 | April 18, 2018 |
| NCT03546634 | Completed | Phase 4 | Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China | May 24, 2018 | January 15, 2020 |
| NCT03554798 | Completed | Phase 2 | A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine | December 4, 2018 | February 19, 2020 |
| NCT05460377 | Enrolling by invitation | Phase 4 | Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine | July 26, 2022 | March 2024 |
| NCT06346834 | Not yet recruiting | Phase 4 | Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers | April 30, 2024 | December 30, 2024 |
| NCT06137664 | Not yet recruiting | Phase 1/Phase 2 | Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines | March 29, 2025 | December 15, 2027 |
| NCT05952596 | Not yet recruiting | Phase 1 | A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults | July 17, 2023 | March 31, 2024 |
| NCT06442449 | Not yet recruiting | Phase 4 | Booster Dose of sIPV Co-administered With MMR and HepA-I. | July 10, 2024 | March 10, 2025 |
| NCT05457946 | Not yet recruiting | Phase 2/Phase 3 | Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series | April 1, 2023 | September 30, 2025 |
| NCT05644184 | Recruiting | Phase 2 | Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh | March 27, 2023 | February 2025 |
| NCT05431933 | Recruiting | Phase 3 | Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants | January 10, 2023 | January 2025 |
| NCT05303545 | Recruiting | Physical Activity in People With Sequelae of Poliomyelitis | May 1, 2022 | December 1, 2023 | |
| NCT05654467 | Recruiting | Phase 2 | Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama | December 5, 2023 | November 20, 2025 |
| NCT05850364 | Recruiting | Phase 3 | A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine | May 22, 2023 | December 1, 2024 |
| NCT05951985 | Recruiting | N/A | High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners | August 15, 2023 | August 14, 2025 |
| NCT04063150 | Terminated | Phase 4 | Immunogenicity of Intramuscular and Intradermal IPV | October 6, 2019 | March 25, 2020 |
| NCT03092791 | Terminated | Phase 1/Phase 2 | IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults | June 7, 2017 | October 18, 2018 |
| NCT01751503 | Terminated | N/A | Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer | March 2013 | December 2019 |
| NCT00871741 | Terminated | Phase 2 | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. | April 1, 2009 | June 25, 2009 |
| NCT03286803 | Unknown status | Phase 4 | Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan | August 1, 2017 | June 30, 2019 |
| NCT01870206 | Unknown status | Phase 3 | Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns | June 2013 | January 2014 |
| NCT04073459 | Unknown status | Phase 2 | Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants | November 2019 | August 2020 |
| NCT03890497 | Unknown status | Phase 4 | Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh | September 27, 2018 | September 2022 |
| NCT04618640 | Unknown status | Phase 3 | To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years | December 26, 2019 | July 30, 2021 |
| NCT03821441 | Unknown status | Phase 3 | Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine | January 4, 2018 | August 2020 |
| NCT03128489 | Withdrawn | Phase 3 | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants | December 1, 2017 | August 1, 2018 |
| NCT05166031 | Withdrawn | Phase 3 | Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine | December 2020 | October 18, 2021 |
| NCT03016949 | Withdrawn | Phase 3 | A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine | July 2017 | November 2018 |
- Disase is a (Disease Ontology)
- DOID:934
- Cross Reference ID (Disease Ontology)
- GARD:7413
- Cross Reference ID (Disease Ontology)
- ICD10CM:A80
- Cross Reference ID (Disease Ontology)
- ICD9CM:045
- Cross Reference ID (Disease Ontology)
- MESH:D011051
- Cross Reference ID (Disease Ontology)
- NCI:C35550
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:54839009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0032371
- OrphaNumber from OrphaNet (Orphanet)
- 2912
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011051